Phase I-II study of DaICM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC). Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Buckman, RA
  • Wong, NS
  • Clemons, M
  • Verma, S
  • Trudeau, ME
  • Roche, K
  • Kerbel, RS
  • Deboer, G
  • Sutherland, DJ
  • Pritchard, Kathleen

publication date

  • June 1, 2005